HAS Reddit Mentions | ChartExchange

\*\*OP DISCLOSURE:\*\*
I announced the BioLargo shareholder town hall and previously disclosed that I am currently bagholding materially more than 1.25% of BioLargo ($BLGO). My average is roughly 40% above today’s price.
I want to be fully transparent: I am significantly underwater on a very large position. However, I recently added approximately $40,000 worth of stock during this dip and have freed up another $10,000 to add.
That is not because I think this is risk-free or because I am ignoring the ugly chart. It is because I believe this is the type of depressed micro-cap situation where the biggest money can be made, if the company converts its pipeline into real contracts, recurring revenue, and better financing terms.
My earlier post introducing the town hall received around 50,000 views:
https://www.reddit.com/r/pennystocks/comments/1wbkz38/blgo\_why\_im\_still\_buying\_holding\_at\_alltime\_lows/
A lot of investors are understandably on the sidelines. I get it. The Pooph loss, Clyra delays, cash burn, dilution risk, and execution concerns are all real.
But I believe the current valuation is putting almost no value on several potentially major assets, subsidiaries, technologies, distributor relationships, and projects.
This is not financial advice. This is my opinion and my position. Please read the filings, listen to the town hall, understand the financing structure, and do your own due diligence.
\---
\*\*THE BIG PICTURE\*\*
All of the following sits inside a company with an approximately $30 million market cap at the time of writing.
That does not automatically mean the stock is cheap. Micro-caps trade at low valuations for reasons. They can be undercapitalized, over-dilutive, difficult to value, poorly understood, and vulnerable to long commercialization timelines.
But $BLGO is not just one early-stage product or one binary technology.
\*\*BioLargo has exposure to:\*\*
\- A core engineering business that management says is effectively self-sustaining/profitable before BioLargo R&D.
\- Clyra Medical, including the FDA-cleared ViaCLYR antimicrobial product line.
\- PFAS treatment and broader industrial-water opportunities.
\- A partnership/alliance with Aquatech for water-treatment opportunities.
\- A potential minerals-facility project that could progress from roughly $1.1 million to approximately $10 million and potentially around $40 million at commercial scale.
\- Tu Nipi Water Solutions and Canadian industrial-water opportunities.
\- A planned company-owned consumer-products relaunch.
\- Cellinity Battery, BioLargo’s long-duration energy-storage subsidiary.
\- Several other subsidiaries and potential licensing, JV, financing, or asset-realization opportunities.
The market is clearly skeptical. It should be. But I think the current valuation reflects an assumption that almost all of these businesses fail, stall indefinitely, or create little value for existing shareholders.
I do not think that is the most likely outcome.
\---
\*\*CEO ALIGNMENT: DENNIS CALVERT HAS THE SAME LOCK-UP STRUCTURE\*\*
This point needs to be stated precisely.
Dennis Calvert has historically had a disclosed base salary under his employment agreement. It would be inaccurate to claim that he receives no compensation whatsoever.
However, in 2026, Calvert accepted BioLargo shares in exchange for reducing amounts the company owed him for salary and unreimbursed business expenses.
Those shares are subject to the same performance and valuation-based lock-up agreement as Kenneth Reay Code’s shares.
Neither Calvert nor Code can sell those locked shares unless one of the following conditions occurs:
1. BioLargo reports at least $40 million in consolidated gross revenue for any reported quarter or annual period.
2. BioLargo’s market capitalization exceeds $300 million.
3. A change-of-control event occurs.
This matters to me.
\*\*At an approximately $30 million market cap, the $300 million threshold is roughly a 10x higher market-cap milestone. The $40 million revenue milestone also represents a dramatically larger operating scale than the company currently reports.\*\*
It does not mean those milestones are guaranteed. They are not.
But it does mean that when Calvert and Code accepted shares instead of amounts owed in cash, the shares came with a restriction that keeps them from selling until BioLargo becomes a substantially larger revenue or market-value company.
That is real alignment in my view. They are not able to simply collect shares and immediately sell them into the market. They only monetize those shares if the company reaches much more meaningful milestones.
\---
\*\*WHY I THINK THE MARKET IS MISSING CLYRA\*\*
Clyra Medical may be the single most overlooked component of BioLargo.
Clyra is commercializing ViaCLYR, an FDA-cleared antimicrobial product line based on its Clyrasept technology. Management has discussed active distribution relationships with:
\- Advanced Solutions
\- Al-Hikma
\- Spartan Medical
Management said these distributors could collectively reach more than 70% of Clyra’s target market.
Advanced Solutions reportedly placed an initial order and carries inventory. Management said it has a sales organization of roughly 350–400 people working across physician offices, wound-care clinics, clinical staff, and healthcare systems.
Spartan Medical has access to military, VA, and GSA channels and has listed multiple ViaCLYR SKUs in its catalog.
Al-Hikma is pursuing regulatory approvals and commercial access in parts of the Middle East.
Clyra has also discussed a possible major national-distribution relationship. Management suggested that setup could take another three to six months once product, operational, and administrative work is complete, with a potential 2027 launch window.
The crucial caveat: distributor agreements are not revenue. Initial orders are not proof of repeat demand. Real validation will come from sell-through, recurring orders, customer adoption, gross margin, and a funding path that does not crush shareholders with additional dilution.
\*\*But the valuation disconnect is worth understanding.\*\*
Management has cited a Clyra valuation of roughly $100 million, and BioLargo owns approximately 48%. On paper, that implies an approximately $48 million value for BioLargo’s stake before discounts for illiquidity, future financing, dilution, Clyra’s ongoing losses, and the fact that private valuations are not liquid cash.
The point is not that Clyra is definitely worth $100 million today.
The point is that a $30 million parent-company market cap appears to be placing very little value on BioLargo’s ownership in Clyra, plus its engineering business, PFAS systems, consumer-products relaunch, Cellinity position, industrial-water projects, and other subsidiaries.
\---
\*\*CELLINITY: BIG UPSIDE, VERY HIGH RISK\*\*
Cellinity is BioLargo’s long-duration battery subsidiary.
Management’s thesis is that Cellinity can provide a grid-scale, liquid-sodium energy-storage technology using abundant materials rather than rare-earth inputs. The company has discussed a model centered on technology, engineering, factory design, and project-level capital, instead of BioLargo personally funding and operating battery factories itself.
Management has cited a previous financing valuation of approximately $33–34 million for Cellinity.
A typical factory has been estimated at around $170 million, with total capital needs around $250 million.
This is absolutely the most speculative section of the BioLargo story.
The risks are obvious:
\- No formal factory agreement has been executed.
\- The business had not generated revenue in the latest reported period.
\- Large battery projects require massive capital and flawless execution.
\- Battery competition is brutal.
\- Lab results or engineering concepts are not the same thing as a financeable commercial plant.
I do not value Cellinity as if success is guaranteed.
I view it as free or very cheap optionality at the parent company’s current valuation. If it secures a credible investor, project partner, manufacturing agreement, offtake, or factory-development deal, sentiment could change quickly.
Until then, it is a high-upside possibility, not an established revenue source.
\---
\*\*PFAS AND INDUSTRIAL WATER: THE CONTRACT-CONVERSION STORY\*\*
BioLargo’s PFAS and industrial-water business is where I think the market could be surprised if even one larger project converts.
Management has discussed:
\- Roughly 20 PFAS trials.
\- A first commercial installation serving as a reference site.
\- Approximately $1.7 million in cumulative water-related revenue since inception.
\- An alliance with Aquatech, a global water-treatment company operating across 32 countries and producing roughly $2 billion in annual revenue.
\- Potential bid opportunities in the roughly $5–10 million range, with some cited opportunities from $20 million to more than $40 million.
The company believes its technology can reduce certain PFAS-treatment operating costs by around 80% compared with some incumbent systems. That needs commercial validation, of course.
The only question that truly matters is whether these trials, discussions, and bids turn into signed revenue contracts.
PFAS is a massive opportunity, but it is also vulnerable to long municipal and industrial sales cycles, regulatory uncertainty, capital budgets, policy delays, procurement hurdles, and customer hesitation.
That is why I am not buying based on PFAS TAM.
I am buying because I think one legitimate large contract would be disproportionately meaningful for a company at a roughly $30 million market cap.
\---
\*\*MINERALS PROJECT AND TU NIPI\*\*
The minerals-facility opportunity is another one I do not think gets enough attention.
Management said the existing approximately $1.1 million minerals-facility contract could progress to a Phase 2 design-build engagement worth approximately $10 million.
If that work performs successfully, management sees a possible commercial-scale project of around $40 million.
Those are not booked numbers. They are potential next stages. But even partial conversion would matter massively at BLGO’s present size.
BioLargo has also formed Tu Nipi Water Solutions to pursue water-treatment opportunities in the Canadian oil-sands and industrial-water market.
The milestones that matter are simple:
\- Named customers, where disclosure permits.
\- Paid pilot work.
\- Signed design contracts.
\- Equipment orders.
\- Commissioned systems.
\- Recurring treatment revenue.
\- Revenue recognition and margins.
Until those arrive, this stays a potential opportunity. If they arrive, this can become one of the most meaningful pieces of the valuation story.
\---
\*\*THE POOPH LOSS AND CONSUMER-PRODUCTS RELAUNCH\*\*
Let’s not sugarcoat it: losing the Pooph relationship was a major setback.
Management said the situation removed roughly $1.6 million of expected Q2 2025 revenue and contributed to an approximately $4 million write-down.
That is part of why the stock has been punished, and it is completely fair for investors to question whether BioLargo can rebuild consumer-products revenue without the former relationship.
The company now plans to launch company-owned consumer products through channels such as Amazon, Shopify, TikTok, social media, and direct-to-consumer marketing. Management has stated that the relaunch is expected in October.
Management’s conservative target is roughly half of Pooph’s prior performance, potentially more than $15 million in revenue over the first 12–18 months after ramping. It also stated that Pooph had generated approximately $125 million in lifetime gross sales and roughly $60 million at peak run rate.
That is a management goal, not a current result.
I will be watching:
\- Whether the launch happens on schedule.
\- Which products and channels go live.
\- Amazon rankings, reviews, and reorder behavior.
\- Product pricing and gross margins.
\- Advertising spend and customer-acquisition costs.
\- Repeat sales versus launch-period promotional sales.
\- Whether the company can build an owned consumer-products platform that does not depend on one partner.
If the relaunch works, it may create revenue faster than the longer-cycle PFAS and industrial-water businesses. If it does not, it will reinforce the concern that Pooph was the company’s main near-term commercial engine.
\---
\*\*WHY I THINK THIS IS MISPRICED\*\*
Management has cited roughly $100 million for Clyra and approximately $33–34 million for Cellinity based on past capital raises.
Taken at face value, those two subsidiary valuations are already larger than BioLargo’s entire current market capitalization.
But investors should discount those figures heavily:
\- BioLargo does not own 100% of Clyra.
\- Private financing valuations can be illiquid and difficult to realize.
\- Subsidiaries may need more capital.
\- Future funding could dilute BioLargo’s ownership.
\- Private-company marks do not equal cash in the parent company’s bank account.
\- The parent has overhead, operating losses, debt/financing needs, and project-execution risk.
Even after applying those discounts, I think there is a real value disconnect.
You have a roughly $30 million market-cap parent company with a meaningful ownership stake in a medical subsidiary that management says was valued around $100 million, a battery subsidiary previously valued around $33–34 million, an engineering operation, PFAS technology, industrial-water projects, a consumer relaunch, and multiple other technologies and subsidiaries.
That does not mean the stock must go up.
It means the valuation is fragile to positive execution. A few real wins, not just announcements, could force investors to revisit what the company is worth.
\---
\*\*MILESTONES I’M WATCHING: NEXT 6–9 MONTHS\*\*
1. Clyra commercial traction
\- Distributor sell-through and repeat orders.
\- Revenue growth rather than just new distribution announcements.
\- Evidence that ViaCLYR is reaching and being adopted by healthcare users.
\- Progress toward a national-distribution launch.
\- Clear disclosure around Clyra financing needs and path toward reduced losses.
2. Consumer-products launch
\- Confirmation of the October launch.
\- Products appearing on Amazon, Shopify, TikTok, and other channels.
\- Actual sales, product reviews, rankings, and reorder data.
\- Gross-margin and marketing-efficiency updates.
\- Evidence of a repeatable company-owned consumer platform.
3. PFAS and water contracts
\- Trial-to-contract conversion.
\- New commercial/reference installations.
\- Aquatech-related project wins.
\- Signed projects in the $5–10 million range or larger.
\- Proof that customers are moving from testing toward procurement.
4. Minerals-facility progression
\- Movement from the existing approximately $1.1 million project toward Phase 2.
\- Confirmation of a roughly $10 million design-build award.
\- Further clarity on the potential commercial-scale opportunity around $40 million.
5. Cellinity validation
\- A credible financing partner, factory-development partner, customer, investor, or offtake agreement.
\- Evidence that the project is moving beyond talks and conceptual planning.
\- A clear explanation of what project capital funds, what BioLargo contributes, and how shareholders participate economically.
6. Capital structure
\- Quarterly share-count changes.
\- Equity-line usage and financing terms.
\- New warrants, conversions, debt, or other dilutive instruments.
\- Whether management can use subsidiary-level funding, project financing, strategic partners, licensing, or non-dilutive capital rather than repeatedly issuing parent-company equity.
\- Cash runway, quarterly burn, and cash generation from the engineering operation.
This is arguably the most important section. Even a strong business opportunity can become a weak investment if the capital structure gets destroyed.
\---
\*\*THE BEAR CASE\*\*
The bear case is completely legitimate:
\- The Pooph separation may be permanently damaging.
\- The consumer-products relaunch may not gain traction.
\- Clyra may continue spending cash faster than it can generate revenue.
\- Distributors may not produce meaningful sales.
\- PFAS trials and bids may fail to become actual contracts.
\- Water and industrial projects may take much longer than investors expect.
\- Cellinity may never achieve commercial-scale funding or validation.
\- Ongoing dilution could overwhelm operational progress.
\- The company may be trying to execute too many initiatives at once.
\- Management timelines could slip repeatedly.
This is why $BLGO is not a “throw money at it and forget it” ticker.
It requires active monitoring and a genuine understanding that this is a very high-risk micro-cap.
\---
\*\*WHY I’M ADDING ANYWAY\*\*
I am not adding because the price is down.
I am adding because I believe the market is currently pricing a near-total failure scenario while several near- and medium-term milestones have the potential to materially change the revenue and valuation conversation.
I am adding because I see a meaningful alignment mechanism in the locked insider shares. Dennis Calvert and Kenneth Reay Code accepted shares subject to the same lock-up, preventing them from selling until the company reaches $40 million in consolidated gross revenue, exceeds a $300 million market cap, or undergoes a change of control.
I am adding because one or two real commercial wins—Clyra sales traction, a PFAS contract, a minerals Phase 2 award, a successful consumer-products launch, or a credible Cellinity deal—could be disproportionately meaningful for a company valued around $30 million.
\*\*I am adding because I believe the upside is much larger than the market currently credits.\*\*
I could be wrong. The company can miss timelines. It can raise more dilutive capital. Its subsidiaries can fail to convert opportunity into revenue. The stock can absolutely go lower.
But this is where I believe asymmetric outcomes can be found: when sentiment is poor, the chart looks terrible, the investor base is exhausted, and the market is not yet pricing in a successful execution path.
\---
\*\*BOTTOM LINE\*\*
$BLGO is a high-risk, execution-dependent micro-cap.
It is not a guaranteed turnaround. It is not a safe investment. It is not a stock anyone should buy because an internet poster has a large position.
But I believe the company is materially undervalued relative to its collection of subsidiaries, projects, technologies, and possible commercial catalysts.
At roughly a $30 million market cap, I think the market is assigning very little value to the possibility that Clyra commercializes, PFAS projects convert, the minerals facility advances, the consumer relaunch works, or Cellinity secures credible development capital.
I am bagholding more than 1.25% of the company at an average roughly 40% above current levels.
I recently added approximately $40,000 on this dip.
I have freed up another $10,000 to add.
That is my conviction level.
Not financial advice.
Do your own due diligence.

document.getElementById("T0kQSJ").onerror = function(){this.style.display='none';}; .dark-mode .WqkM87{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .WqkM87{ color: #333333; background-color: white; border: 2px solid #333333; }HASHasbro, Inc.stock NASDAQ

HAS
Hasbro, Inc.
stock NASDAQ